1. Introduction

Certain medical conditions require regular or repeated blood transfusions for survival and improved quality of life. These transfusion‑dependent patients include those with thalassemia major, severe haemophilia (requiring clotting factors), leukaemia patients undergoing chemotherapy, aplastic anaemia, and other chronic hematologic disorders.

2. Categories of Transfusion‑Dependent Patients

a. Thalassemia Major:

– A hereditary hemoglobinopathy causing severe anaemia.

– Patients require lifelong regular transfusions, typically every 2–4 weeks.

b. Haemophilia (A and B):

– A congenital deficiency of clotting factors VIII (A) or IX (B).

– Patients generally require factor concentrates rather than whole blood, but may occasionally need plasma or cryoprecipitate.

c. Leukaemia Patients:

– Often require red cells, platelets, and plasma due to marrow suppression from disease or chemotherapy.

– Platelet transfusions may be needed frequently.

d. Aplastic Anaemia:

– Reduced bone marrow function leads to low RBCs, WBCs, and platelets.

– Frequent RBC and platelet transfusions are needed.

e. Other Conditions:

– Myelodysplastic syndromes, advanced kidney disease, autoimmune haemolytic anaemia, congenital anaemia.

3. Blood Component Requirements

a. Packed Red Blood Cells (PRBCs):

– Required for chronic anaemia such as thalassemia or aplastic anaemia.

– Typical frequency: every 3–4 weeks (thalassemia) depending on pre‑transfusion haemoglobin levels.

b. Platelets:

– Required for leukaemia patients undergoing chemotherapy and aplastic anaemia patients.

– Frequency depends on platelet count; can be several units weekly.

c. Fresh Frozen Plasma (FFP):

– For coagulation deficiencies, disseminated intravascular coagulation, or liver dysfunction.

d. Cryoprecipitate:

– Used for fibrinogen deficiency, Factor XIII deficiency, and sometimes haemophilia where factor concentrates are unavailable.

e. Factor Concentrates:

– First‑line treatment for haemophilia A and B.

– Recombinant factors preferred due to low infection risk.

4. Blood Usage Pattern

– Thalassemia patients may require 12–18 PRBC transfusions per year.

– Leukaemia patients may require multiple platelet units per week during intensive chemotherapy.

– Aplastic anaemia patients may require lifelong transfusion support.

– Haemophilia patients require factor concentrates on demand or prophylactically.

5. Risk Factors Associated with Repeated Transfusions

a. Transfusion‑Transmitted Infections (TTIs):

– Hepatitis B, Hepatitis C, HIV (risk minimized through mandatory screening).

b. Iron Overload:

– Common in thalassemia and chronic anaemia patients.

– Leads to liver, heart, and endocrine organ damage; requires chelation therapy.

c. Alloimmunisation:

– Development of antibodies against donor RBC antigens, complicating future transfusions.

d. Transfusion Reactions:

– Acute haemolytic reactions, febrile reactions, allergic reactions, TRALI, TACO.

e. Immune Suppression:

– Frequent transfusions can cause immune modulation.

6. Precautionary Measures in Blood Transfusion‑Dependent Patients

a. Extended RBC Typing:

– Provide phenotype‑matched or genotype‑matched blood for thalassemia and chronic transfusion cases.

b. Use of Leukoreduced Components:

– Reduces febrile reactions, alloimmunisation, and CMV transmission.

c. Iron Overload Monitoring:

– Regular ferritin testing and MRI T2* for liver/heart iron.

– Use of iron chelation therapy.

d. Closely Monitored Transfusion Practices:

– Vital signs monitoring, proper cross match, and transfusion rate control.

e. Use of Recombinant Factors in Haemophilia:

– Reduces exposure to blood components.

f. Infection Screening:

– Regular monitoring for HBV/HCV/HIV in chronically transfused patients.

g. Patient Education:

– Importance of adherence to transfusion schedules.

– Awareness of symptoms of transfusion reactions.

– Importance of maintaining iron chelation therapy.

7. Conclusion

Transfusion‑dependent patients require lifelong, well‑regulated blood component therapy. Safe transfusion practices, continuous monitoring, and appropriate selection of blood components are essential to minimize complications and improve patient outcomes.